Document Detail


Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survival at 6 hours but not at discharge.
MedLine Citation:
PMID:  23354229     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Despite poor evidence and high costs, fibrinogen concentrate (FC) represents one of the most frequently used hemostatic agents in exsanguinating trauma. The aim was to assess whether the administration of FC in severely injured patients was associated with improved outcomes.
METHODS: Patients documented in the Trauma Registry of the German Society for Trauma Surgery (primary admissions, Injury Severity Score [ISS] ≥16) who had received FC during initial care between emergency department (ED) arrival and intensive care unit admission (FC+) were matched with patients who had not received FC (FC-).
RESULTS: The matched-pairs analysis yielded two comparable cohorts (n = 294 in each group) with a mean ISS of 37.6 ± 13.7 (FC+) and 37.1 ± 13.3 (FC-) (p = 0.73); the mean age was 40 ± 17 versus 40 ± 16 (p = 0.72), respectively. Patients were predominantly male (71.1% in both groups, p = 1.0). On emergency department arrival, hypotension (systolic blood pressure, ≤90 mm Hg) occurred in 51.4% (FC+) and 48.0% (FC-) (p = 0.41), and base excess was -7.4 ± 5.3 mmol/L for FC+ and was -7.5 ± 6.2 mmol/L for FC- (p = 0.96). Patients were administered 12.8 ± 14.3 (FC+) versus 11.3 ± 10.0 (FC-) packed red blood cell units (p = 0.20). Thromboembolism occurred in 6.8% (FC+) versus 3.4% (FC-) (p = 0.06), and multiple organ failure occurred in 61.2% versus 49.0% (p = 0.003), respectively. Whereas 6-hour mortality was 10.5% for FC+ versus 16.7% for FC- (p = 0.03), the mean time to death was 7.5 ± 14.6 days versus 4.7 ± 8.6 days (p = 0.006). The overall hospital mortality rate was 28.6% versus 25.5% (p = 0.40), respectively.
CONCLUSION: This is the first study to investigate the effect of FC administration in bleeding trauma. In our large population of severely injured patients, the early use of FC was associated with a significantly lower 6-hour mortality and an increased time to death, but also an increased rate of multiple organ failure. A reduction of overall hospital mortality was not observed in patients receiving FC.
LEVEL OF EVIDENCE: Therapeutic study, level IV.
Authors:
Arasch Wafaisade; Rolf Lefering; Marc Maegele; Thomas Brockamp; Manuel Mutschler; Sven Lendemans; Marc Banerjee; Bertil Bouillon; Christian Probst;
Related Documents :
12928679 - Scleral explant removal: the last decade.
23622919 - High mortality risks after major lower extremity amputation in medicare patients with p...
16483659 - Ranibizumab for treatment of neovascular age-related macular degeneration: a phase i/ii...
8926129 - Delayed suprachoroidal hemorrhage after penetrating keratoplasty.
18348019 - Prognostic factors of postoperative visual outcomes in tuberculum sellae meningioma.
15197059 - Neutralizing tumor necrosis factor activity leads to remission in patients with refract...
11728269 - Comparison of subcutaneous calcium heparin and acetylsalicylic acid in the prevention o...
10776819 - Surgery for tricuspid valve endocarditis: a selective approach.
3171849 - Paraesophageal hernia after nissen fundoplication: a real complication in pediatric pat...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The journal of trauma and acute care surgery     Volume:  74     ISSN:  2163-0763     ISO Abbreviation:  J Trauma Acute Care Surg     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-28     Completed Date:  2013-04-05     Revised Date:  2013-11-04    
Medline Journal Info:
Nlm Unique ID:  101570622     Medline TA:  J Trauma Acute Care Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  387-3; discussion 393-5     Citation Subset:  AIM; IM    
Affiliation:
Department of Trauma and Orthopedic Surgery, University of Witten/Herdecke, Cologne-Merheim Medical Center, Cologne, Germany. wafaisadea@kliniken-koeln.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Exsanguination / drug therapy*,  etiology,  mortality
Female
Fibrinogen / administration & dosage,  therapeutic use*
Hemostatics / administration & dosage,  therapeutic use*
Hospital Mortality
Humans
Male
Survival Analysis
Time Factors
Wounds and Injuries / complications
Chemical
Reg. No./Substance:
0/Hemostatics; 9001-32-5/Fibrinogen
Comments/Corrections
Comment In:
J Trauma Acute Care Surg. 2013 Oct;75(4):744-5   [PMID:  24064895 ]
J Trauma Acute Care Surg. 2013 Oct;75(4):745-6   [PMID:  24064896 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penet...
Next Document:  Redefining massive transfusion when every second counts.